WSTAM
BIIB icon

Wilbanks Smith & Thomas Asset Management’s Biogen BIIB Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-37
Closed -$13K – 454
2018
Q3 		$13K Buy
+37
New +$12.7K ﹤0.01% 979

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's BIIB Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Biogen (BIIB) in Q4 2018, closing a stake of 37 shares — an estimated $13K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in BIIB in Q3 2018 and held it in 1 quarter. The position peaked at $13K in Q3 2018. 1,140 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 37 Biogen shares in Q4 2018, an estimated $13K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Biogen in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Biogen position peaked at $13K in Q3 2018.
  • 1,140 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.